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Abstract
Enteroviruses are small, non-enveloped, positive-sense single-
strand RNA viruses, and are ubiquitously found throughout the 
world. These viruses usually cause asymptomatic or mild febrile 
illnesses, but have a propensity to induce severe diseases in-
cluding type 1 diabetes and pancreatitis, paralysis and neuroin-
flammatory disease, myocarditis, or hepatitis. This pathogenic-
ity may result from induction of autoimmunity to organ-specific 
antigens. While enterovirus-triggered autoimmunity can arise 
from multiple mechanisms including antigenic mimicry and re-
lease of sequestered antigens, the recent demonstration of T 
cells expressing dual T cell receptors arising as a natural conse-
quence of Theiler’s virus infection is the first demonstration of 
this autoimmune mechanism. 
Picornaviruses are non-enveloped, small, single-stranded 
positive-sense RNA genome viruses. The genome consists of 
approximately 7500 nucleotides containing an open reading 
frame flanked by a 5′ and 3′ untranslated region (UTR), and 
the 5′ UTR equipped with a highly conserved internal ribo-
some entry site [1]. The open reading frame is translated into 
a single polypeptide which is subsequently processed by vi-
ral proteases into 11–12 individual viral proteins. The fam-
ily comprises enteroviruses (EVs), hepatoviruses, parecho-
viruses, rhinoviruses, aphthoviruses, and cardioviruses [2]. 
Although aphthoviruses and cardioviruses have been histor-
ically deemed animal pathogens, a recently isolated human 
cardiovirus — saffold virus — in a child with febrile illness, 
indicates human pathogenesis is possible, can occur world-
wide, and can primarily infect children under six years of age 
[3]. Other new picornavirus genera include Cosavirus and Ko-
buvirus, but little is known about them [4]. Human EVs are 
subgrouped into polioviruses (PVs; 3 serotypes), coxsackie-
virus A (CVAs; 23 serotypes), coxsackievirus B (CVBs; 6 sero-
types), echoviruses (28 serotypes), and EVs 68–72. EV infec-
tions in humans are predominantly asymptomatic or cause 
minor respiratory illnesses. However, more severe outcomes, 
including type 1 diabetes, paralysis, myocarditis, and menin-
goencephalitis, are often associated with various EV infec-
tions [4–7,8*]. 
EV infections are relatively common and confirmed cases 
are voluntarily documented in the Centers for Disease Control 
Morbidity and Mortality Weekly Report. During surveillance 
between 1970 and 2005 [9], 52,812 detections of EV were 
reported to the Centers for Disease Control in the United 
States, but the dominant forms of EV varied from year to year. 
The total number of EV infections decreased after 1990 but 
increased again in 2000. Of all reported EV infections during 
that time frame, infection with CVB4 (9.8%), CVB2 (5.9%), and 
CVB3 (5.4%) resulted in the highest fatal outcomes. CVBs are 
distributed throughout the world based on antibody serop-
revalence and the lowest numbers reported were 6.7–21.6% 
in Greece with the highest being over 50% in China [10,11]. 
EV-D68 recurred seasonally in the Netherlands between 2011 
and 2014, primarily affecting individuals who were less than 
20 years old and between the ages of 50 and 59. In 2014, an 
EV-D68 outbreak in the United States resulted in 1152 con-
firmed cases; interestingly, mainly children were affected and 
disease was associated with flaccid myelitis [12,13]. Although 
EVs occur everywhere in the world, enteroviral pathogenesis 
may be more pronounced in certain geographic regions than 
others. For instance, there are recurrent outbreaks of EV-71 
in the Asia-Pacific region. The outbreaks predominantly af-
flict children with hand-foot-and-mouth disease and occa-
sionally more serious complications, such as aseptic menin-
gitis, acute flaccid paralysis, and brainstem encephalitis and/
or severe pulmonary edema and shock [14]. Generally, out-
breaks of EV-71 have been sporadic or small- clustered in Af-
rica, Europe, and North America and only rarely accompanied 
by severe complications [14]. The incidence and severity of 
EV-71’s pathogenicity in the Asia-Pacific region is not com-
pletely understood, but a genetic link between human leu-
kocyte antigen (HLA)- A33 and EV pathogenesis has been 
reported [15]. It should be noted that HLA-A33 is frequently 
found in Asian populations but rarely occurs in non-Asians.
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One of the major features of severe pathogenic diseases 
as a result of several picornavirus infections (type 1 diabe-
tes, myocarditis, or paralysis) is a strong association with 
autoimmunity. This is especially true in type 1 diabetes [16] 
and myocarditis [17,18]. Although PV-induced paralysis 
does not appear to be the result of an immunopathogenic 
mechanism (resulting instead from direct viral infection and 
neuronal destruction), another member of the picornavi-
rus family, Theiler’s murine encephalomyelitis virus (TMEV), 
is often used as a murine model of virus-induced multiple 
sclerosis to induce T-cell-mediated autoimmune demyelin-
ating disease [19,20]. Although the link between autoim-
munity and microbial infections is not novel, what remains 
highly controversial is the role infection may play in autoim-
munity. The simplest explanation may be that infection with 
cytopathic infectious agents results in cell death or injury, 
thus releasing either sequestered or cellular autoantigens 
which are present at low concentrations before infection, 
thus preventing autosensitization (Figure 1). Self-reactive 
T-cell clones should be deleted in the thymus during T-cell 
ontogeny when thymic epithelial cells present autoantigens 
(central tolerance) but this process requires the autoantigen 
to be available to the epithelial cells. Thus, it follows that T 
cells reactive to cardiac myosin, myelin basic protein, or islet 
beta cells would most probably escape central tolerance as 
these antigens are not present in the thymus during T cell 
ontogeny (Figure 1). Also, T cells with low affinity self-re-
active TCR could escape clonal deletion within the thymus. 
When organs such as the heart, islets or CNS undergo sub-
stantial damage and release of normally sequestered anti-
gens; breakdown of the blood brain barrier; or chemokine 
induced infiltration of the damaged tissue with leukocytes; 
Figure 1. Proposed autoimmune mechanisms in picornaviral infections. (1) Viruses, depending on their tropism for various organ 
systems, such as cardiovascular, digestive, and central nervous system, can directly damage target organs, leading to the release 
of self-antigens, including those located within the cells. The newly released antigens are then taken up by dendritic cells, and af-
ter processing, self-peptides presented by dendritic cells may trigger induction of potentially pathogenic self-reactive T cells. Alter-
natively, autoreactive B cells can also take up these antigens and produce autoantibodies that then contribute to tissue damage by 
activating immune complex-mediated complements. (2) Acute damage can also result when innate immune cells such as macro-
phages and dendritic cells engage in excessive inflammatory cytokine production. Likewise, IFN-I, when produced in excess by vi-
rus-infected cells, can contribute to tissue damage. (3) Exposure to viruses carrying mimicry sequences for self-antigens can lead to 
the generation of cross-reactive T-cell and antibody responses. Whereas T cells can induce damage through delayed-type hyper-
sensitivity reaction (CD4 T-cell-dependent) and cytolysis (CD8 T-cell-dependent), autoantibodies mediate tissue damage via com-
plement activation. (4) Alternatively, if T cells bearing dual receptors (presumably one receptor specific for the foreign antigen and 
the other for self-antigen) are responsive to viral infections, by virtue of their response to viruses, they could also potentially attack 
self-tissues in the context of mistaken identity. In all of these scenarios, once self-tissues are damaged, de novo generation of self-re-
active T and B cells precipitate the disease process, leading to chronicity as observed in many organ-specific autoimmune diseases.
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the low-affinity self-reactive T cells or T cells reactive to se-
questered antigens may encounter appropriately presented 
self-antigens by professional antigen presenting cells at ad-
equate MHC-peptide threshold levels and with appropriate 
accessory molecule stimulation and cytokines necessary for 
their activation and proliferation. This process, designated 
bystander activation, may initially lack vigor as the T cells 
would be low affinity. However, since TCR have the poten-
tial to undergo somatic mutations during replication, there 
is the potential to evolve higher affinity and a broadening of 
reactivity (epitope spreading) self-reactivity over time. Thus, 
autoimmunity may evolve for months or even longer before 
pathogenic disease becomes evidence [21]. 
EVs activate the RIG-I-like helicase melanoma differenti-
ation gene 5 (MDA5) [22], which in turn stimulates the ac-
tivation of interferon regulatory transcription factors (IRFs) 
3 and 7 and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) via the common adaptor mito-
chondrial antiviral-signaling protein. Activation of IRF3/7 re-
sults in type 1 interferon (IFN-I) expression, whereas nuclear 
translocation of NF-κB leads to the upregulation of many 
cytokine, chemokine, and accessory molecules involved in 
host defense [23,24]. MDA5 activation may directly result in 
autoimmunity post picornaviral infection because (a) gain-
of-function mutations in MDA5 are associated with spon-
taneous lupus-like autoimmunity induction in mice [25]; (b) 
chronic, high-level expression of IFN-I results in lupus-like 
conditions [26]; and (c) transgenic mice expressing multiple 
copies of the MDA5 gene (Ifih1) are more prone to autoim-
munity [27*]. The results of these animal studies have been 
corroborated in patients having naturally occurring gain-of-
function mutations in Ifih1 which resulted in neuroimmuno-
logical disease, and MDA5 showing increased RNA binding 
avidity and IFN signature [28*]. Because several picorna-
viruses, including PV [29], CVB [30], and foot-and-mouth 
disease [31], can induce persistent viral infections, chronic 
activation of MDA5 and upregulation of IFN-I could pro-
duce the adjuvant effect attributed by some investigators 
as the major contributing factor in picornavirus infections 
to induce autoimmunity [32]. While MDA5 activation and an 
IFN-I signature are implicated in autoimmunity induction, 
other potential mechanisms should be considered as well. 
With the increased use of IFN-I in chronic hepatitis C treat-
ment, there are now more reports of side effects leading 
to dilated cardiomyopathies [33–38] and prolonged treat-
ment with PEGylated IFN-I was associated with cardiomy-
opathies with poor prognosis [33]. The mechanism under-
lying IFN-I-induced cardiomyopathy is unknown, but it has 
been suggested that cardiomyopathy could be the result of 
impaired myocyte metabolism rather than histological dam-
age [38]. High IFN-I levels resulting from picornavirus in-
fections could also result in impaired myocyte metabolism 
which itself could be pathologic or could lead to myocyte 
necrosis/apoptosis and release of autoantigens. This would 
explain why picornaviruses can effectively result in the man-
ifestation of a range of autoimmune diseases: since the in-
fection specifically produces an environment that attracts 
and promotes activation of T cells and antigen-presenting 
cells to damaged tissues or self-antigens released as a con-
sequence of infection. This hypothesis differs from another 
current major theory for virus-induced autoimmunity — an-
tigenic mimicry — that assumes the sharing of peptide epi-
topes between the infectious agent and self-molecules, thus 
necessitating proteins or peptides from viruses such as CVB 
to mimic multiple autoantigens.
Antigenic mimicry, the shared sequence or tertiary struc-
ture between foreign and self-antigens, has long been con-
sidered the most popular and well-established theory [39]. 
Pathogenic mimicry between specific pathogens (group A 
streptococcus and Campylobacter jejuni, respectively) and 
tissues is well documented [40–42] in rheumatic heart dis-
ease and Guillain–Barré syndrome. Strong evidence sug-
gests that picornavirus infections induce experimental au-
toimmunity at both T-lymphocyte and B-lymphocyte levels. 
Cardiac myosin autoantibodies occur in CVB3-infected mice 
with developing myocarditis, and passive administration of 
autoantibodies can transfer disease [43,44]. At least a por-
tion of these antimyosin antibodies are cross-reactive to 
CVB3 as well as group A streptococcus [45]. These antibod-
ies react to alpha helical sequences, thus possibly explaining 
the broad cross-reactivity of cross-reactive anti-streptococ-
cal antibodies to cardiac myosin and many other tissue an-
tigens, including tropomyosin, laminin, vimentin, and kera-
tin [41]. Similarly, CVB3-infected mice can generate CD4+ T 
cells capable of transferring myocarditis to naïve mice [46]. 
Other studies have found cross-reactivity between NT4 pep-
tides in group A streptococcus, cardiac myosin, and CVB3 
and have shown that mice tolerized to this cross-reactive 
peptide abrogated induction of CVB3-myocarditis, indicat-
ing that the mimicking epitope was a major pathogenic fac-
tor in the experimental disease [47].
The mimicry hypothesis has also been tested in the con-
text of type 1 diabetes, but little evidence exists to support 
this mechanism [48]. For example, glutamate decarboxylase 
(GAD) 247–279, and a peptide fragment derived from CVB 
protein (P2-C, amino acids 32–47), have been shown to in-
duce T cell responses in type 1 diabetes patients [49]. Con-
versely, T cell clones specific to GAD 247–280 generated from 
type 1 diabetes patients failed to react with its mimicry epi-
tope, P2C 28–50, a derivative of P2-C protein from CVB [50]. 
Paradoxically however, infection of BDC2.5 T-cell receptor 
(TCR) transgenic mice with CVB4 led to the development of 
diabetes rapidly, probably due to the release of autoanti-
gens, leading to bystander activation of autoreactive T cells 
[51]. Thus, the relevance of molecular mimicry to the immune 
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pathogenesis of type I diabetes continues to be uncertain. 
Similarly, although, upregulation of costimulatory molecules 
in the inflammatory microenvironment is believed to break 
the self-tolerance by activating the bystander T cells, targeted 
expression of IL-2 or IL-12 in the pancreatic β cells to pro-
mote continuous proliferation of T cells and/or induction of 
Th1 cytokines failed to initiate the disease [52,53]. Likewise, 
induction of type 1 interferon response did not trigger diabe-
tes in TCR transgenic mice [54]. Thus, bystander activation as 
an underlying immune mechanism of diabetes lacks a good 
experimental evidence. However, it may be possible that the 
release of sequestered antigens secondary to primary dam-
age, if any, can possibly act as putative target auto-antigens, 
as BDC2.5 TCR transgenic mice treated with subdiabetogenic 
doses of streptozotocin that causes damage to the pancre-
atic islets, developed diabetes spontaneously [54].
Although humoral cross-reactivity is commonly under-
stood as antibodies that typically react to tertiary structures 
such as alpha helices (which are common among proteins), 
cross-reactivity between T-cell epitopes might initially seem 
less probably, since, primary amino acid sequences must be 
loaded onto major histocompatibility complex (MHC) anti-
gens and presented to the TCR. However, it is now accepted 
that there is substantial TCR degeneracy in epitope recog-
nition because, amino acids are recognized by the chemi-
cal properties they share rather than the need for a specific 
amino acid at a specific location within the peptide sequence 
[55,56]. Indeed, one investigator concluded that the sharing 
of just one amino acid between two peptides may be suffi-
cient for T-cell cross-reactivity to occur [57]. Such flexibility in 
the recognition of peptides by T cells may make singling out 
antigenic mimicry as a cause of autoimmunity in viral infec-
tion difficult. A second point of note is that antigenic mim-
icry alone may not adequately support autoimmune disease, 
despite sensitizing autoreactive T or B cells. von Herrath and 
colleagues proposed a “fertile-field hypothesis” [58] in that, 
encounter with a virus or microbe bearing mimicry epitope 
for self-antigens may not always necessarily results in disease 
[59]. Instead, exposure to infectious pathogens may lead to 
the generation of auto-reactive cells as a result of their mul-
tiplication within the target tissues (heart, brain or pancreas). 
Once such repertoires are formed, future encounters with 
unrelated microbes could possibly trigger pathogenic au-
toimmune responses non- specifically through the adjuvant 
effects of microbes or bystander activation. Similarly, serial 
infection or exposing individuals with cross-reactive epitopes 
to self-antigens such as cardiac myosin and a multitude of 
different microbes/agents could reactivate autoimmune re-
sponses, leading to ever-more potent memory T cells until 
a substantial or chronic degenerative condition is achieved. 
Studies by Massilamany et al. [60] demonstrated that epi-
topes in Bacillus sp. NRRL B-14911, Magnetospirillum gry-
phiswaldense, Cryptococcus neoformans, and Zea mays have 
a shared sequence identity with the myocarditic epitope in 
cardiac myosin heavy chain-α and have varying capacities 
to induce myocarditis when injected into mice. As indicated 
above, CVB3 and group A streptococcus NT4 peptide share 
a mimicking epitope with cardiac myosin, and tolerization of 
mice to the NT4 peptide, abrogated subsequent induction 
of myocarditis via CVB3.
Another potential mechanism for picornaviral induction 
of autoimmunity is T-cell expression of dual TCRs (Figure 1). 
Although, it was originally thought that T cells generated a 
single V-(D)-J rearrangement during T-cell ontogeny in the 
thymus, it is now known that approximately 30% of T cells in 
humans and 15% in mice express TCR with two different Vα 
rearrangements and therefore different antigen specificities 
[61–63]. By contrast, considerably fewer T cells express dual 
Vβ TCR (15% in humans and 5–7% in mice) [61,64,65]. Be-
cause the total space available for TCRs on a plasma mem-
brane must be divided between the two types TCRs, when 
one of them is autoimmune, the level of stimulation dual 
TCR-bearing T cells receive in the thymus may be insufficient 
to result in clonal deletion. Furthermore, when the TCR that 
is reactive to foreign antigen activates the T cell, the cell will 
subsequently be primed to respond to self-antigens through 
self-reactive TCR, thus breaking self-tolerance. This hypoth-
esis is supported by studies in a KRN autoimmune arthritis 
mouse model using transgenically produced dual TCR-bear-
ing T cells with a capacity to avoid clonal deletion in the thy-
mus and drive spontaneous late-onset autoimmune arthritis 
[66**]. Although this model depended on transgenic T cells, 
studies by Libbey and colleagues [67] using TMEV provide 
strong evidence that dual TCR-bearing T cells may drive au-
toimmunity in picornaviral infections [61]. Both Vβ3 and Vβ6, 
as well as multiple Vα proteins, have been detected in TMEV-
induced CD8+ T cells capable of adoptively transferring flac-
cid paralysis. However, the authors were not able to deter-
mine the individual TCR antigen specificities in the TMEV 
model, although the investigation appears to be ongoing. 
Should future studies reveal the natural coexistence of self-
reactive and virus-specific TCR on the same T cell, this would 
be the first demonstration of a virus-induced autoimmunity 
through this mechanism.
In summary, autoimmunity has been shown to occur as 
a consequence in three experimental picornavirus infection 
models: CVB3-induced myocarditis, CVB4-induced type 1 
diabetes and TMEV-induced demyelinating central nervous 
system disease. In all the three models, viruses damage tar-
get organs (heart and pancreas in CVB and brain and spi-
nal cord in TMEV), leading to the secondary generation of 
autoimmune responses. The exact mechanism or mecha-
nisms inducing this autoimmunity remain controversial, al-
though evidence supporting several proposals exists: adju-
vants and release of sequestered self-antigens from virally 
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damaged cells, antigenic mimicry, or dual TCR expression. 
Distinct methods for induction of autoimmunity could po-
tentially dominate either under different conditions or in 
different individuals. Additionally, self-reactive immune re-
sponses may not necessarily be pathogenic in all conditions 
[68,69,70**,71]. The challenge lies in proving causal links be-
tween the infectious agent, the physiological response in-
duced by the host (which might persist subclinically for weeks 
or months), and the ultimate clinical outcome. Finally, not all 
individuals infected with picornaviral infection show equiva-
lent disease susceptibility. As indicated above, EV-71-induced 
pathology may be more severe in individuals with HLA-A33 
[72]. Similarly, HLA-A3, HLA-B40, and HLA-Cw2 may increase 
susceptibility to CVB-induced myocarditis [73]. In an experi-
mental model, host genetics clearly determined viral patho-
genesis, as the same virus that infected inbred mouse strains 
resulted in either no autoimmunity and no disease or pro-
duced severe autoimmunity with accompanying pathology 
[74]. Thus, it would be erroneous to assume that anyone in-
fected with potential pathogens will develop autoimmune 
diseases. It is unclear whether well-controlled epidemiolog-
ical studies can determine if this supposed relationship be-
tween various genetic markers and infections even exists. The 
uncertainty lies in the time lag between initial infection and 
the clinical appearance of symptoms, the latter possibly tak-
ing weeks or months to manifest. Until this kind of epidemi-
ological study can identify cause-and-effect relationships in 
a human setting, experimental models remain the only tool 
available to systematically research autoimmune events.
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